THE SALGI ESOPHAGEAL CANCER RESEARCH FOUNDATION (EIN 453633809) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2011

Legal Domicile

Principal Officer

LINDA M MOLFESI

Phone

4013987785

Tax Period

2024-12-01 to 2025-11-30

THE SALGI ESOPHAGEAL CANCER RESEARCH FOUNDATION, founded in 2011, is a small nonprofit in the Medical Research sector that reported $153K in total revenue in fiscal year 2024. Revenue surged 38% from the prior year, signaling strong growth momentum. Expenses of $276K exceeded revenue, resulting in a 81% operating deficit.

Mission

THE ORGANIZATIONS MISSION IS TO RAISE FUNDS FOR AWARENESS, EARLY DETECTION AND RESEARCH OF ESOPHAGEAL CANCER IN HOPES OF A CURE.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $144,169

Program Service Revenue $0

Investment Income $9,057

Other Revenue $-683

TOTAL REVENUE $152,543

Expense Breakdown

Grants Paid $249,190

Salaries & Benefits $11,668

Fundraising Expenses $9,990

Program Expenses $255,393

Other Expenses $15,535

TOTAL EXPENSES $276,393

Year-over-Year Comparison

	2024	2023	Change
Revenue	$152,543	$110,298	+0.4%
Expenses	$276,393	$22,238	+11.4%
Net Income	$-123,850	$88,060	-2.4%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$9,600

Total Directors

$9,600

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
CHRISTINA M FRYE	VICE PRESIDENT	10.00	Officer Director	$9,600	$0	$9,600
JAMES W FRYE	SECRETARY	10.00	Officer Director	$0	$0	$0
LINDA M MOLFESI	PRESIDENT & TREASURER	10.00	Officer Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$152,543	$276,393	$472,567	$-123,850
2024	$110,298	$22,238	$596,417	$88,060
2023	$100,781	$147,370	$508,357	$-46,589
2022	$136,637	$18,083	$554,946	$118,554
2020	$90,543	$14,400	$342,323	$76,143
2019	$93,484	$12,788	$266,180	$80,696
2018	$93,631	$73,292	$185,484	$20,339

THE SALGI ESOPHAGEAL CANCER RESEARCH FOUNDATION